bmiMD Review 2026: Honest Take on Their Semaglutide & Tirzepatide Telehealth

GLP-1 receptor agonists (Semaglutide, Tirzepatide) are arguably the most consequential pharmacology development of the past decade for metabolic health. The longevity-research framing has shifted: these aren't weight-loss drugs, they're cardiometabolic interventions with substantial all-cause mortality reduction signals in the SELECT trial (Lincoff et al., NEJM 2023) and emerging cognitive-protection signals in active trials.

For longevity-curious buyers wanting to access these compounds outside the brand-name ($1,400-1,800/mo for Wegovy or Zepbound) the telehealth-compounded route exists. bmiMD is one of the established players. This is the honest review on whether it's the right pick.

What bmiMD actually is

bmiMD is a US-based telehealth program that prescribes and ships compounded Semaglutide ($249/mo) and Tirzepatide ($349/mo) — the same active ingredients as Wegovy/Ozempic and Zepbound/Mounjaro respectively, but compounded by FDA-licensed pharmacies rather than purchased branded.

The program flow: 1. 5-minute online questionnaire covering medical history 2. Video or async consult with a US-licensed physician 3. Lab work via in-network draw or mail-in panel 4. Prescription approval and monthly shipment 5. Ongoing physician check-ins quarterly with dose titration

bmiMD's positioning vs other GLP-1 telehealth (Mochi, Ro, Hims, Henry Meds, Future Health): - 60,000+ active members (largest US compounded GLP-1 telehealth) - 4.9 star rating across review platforms - Pricing in the middle of the market (Mochi at $199-269, Ro at $169-249 for Semaglutide; bmiMD at $249-349) - US-only operations (no international shipping) - Member portal and ongoing physician relationship — not a one-time prescription mill

The compliance and quality posture

The legitimate GLP-1 telehealth question isn't "does it work" (the active compounds are well-characterized) but "is the source legitimate." The compounded pharmacy regulatory environment shifted significantly in 2024-2025 with Eli Lilly and Novo Nordisk pursuing legal action against compounded suppliers selling under brand-equivalent claims. The FDA's 503A and 503B pharmacy regulations distinguish patient-specific compounding (which remains legal) from bulk compounding (which has been increasingly restricted).

bmiMD operates under 503A patient-specific compounding through its pharmacy partners. Each prescription is patient-specific (your name, your dose, your titration schedule). This is meaningfully different from the bulk-compounded products that triggered FDA enforcement actions against several other operators.

The active compound is identical to brand-name. The dose is titrated to clinical guidelines (start at 0.25 mg Semaglutide weekly, escalate to 1-2.4 mg per cardiologist guidance and patient response). The delivery is auto-injector pens or vials with syringes depending on formulation.

Who bmiMD is the right call for

• Buyers wanting Semaglutide or Tirzepatide outside the $1,400-1,800/mo brand pricing without dealing with the international pharmacy gray market
• Longevity-curious users wanting to access GLP-1 receptor agonists as a metabolic intervention rather than for weight loss specifically (off-label use is common in longevity practice)
• Users with insulin resistance, prediabetes, NAFLD, or obesity-related cardiometabolic risk markers who haven't qualified for branded coverage through insurance but want clinical-quality access
• Buyers who want US-licensed physician oversight and monthly accountability rather than a one-shot international pharmacy purchase

Who should skip it

• You qualify for insurance-covered Wegovy or Zepbound — go through your existing physician and insurance. Insurance coverage at $25-100 monthly co-pay is meaningfully better than $249-349 cash.
• You want to manage GLP-1 therapy without ongoing physician relationship — bmiMD requires quarterly check-ins. Some other operators are more lightweight, but the trade-off is reduced safety monitoring.
• You're in a state where bmiMD doesn't operate — verify state coverage on their site before applying. The compounded telehealth space has variable state regulations.
• You have contraindications — personal or family history of medullary thyroid carcinoma, MEN2, severe gastroparesis, active pancreatitis, or pregnancy/breastfeeding. The screening process flags these but verify with your existing clinician.

Cost math

• Semaglutide via bmiMD: $249/mo = $2,988/year
• Tirzepatide via bmiMD: $349/mo = $4,188/year
• Wegovy/Zepbound brand without insurance: ~$1,400-1,800/mo = $16,800-21,600/year
• Wegovy/Zepbound with insurance (when covered): $25-100/mo = $300-1,200/year

For uninsured buyers, bmiMD is 5-7x cheaper than brand. For insured buyers with coverage, brand is cheaper. The compounded telehealth route exists for the gap between these two.

The longevity-stack frame

For Lifespan Vault's longevity-focused readership, the GLP-1 question isn't primarily about weight. It's about whether GLP-1 receptor activation is a worthwhile metabolic intervention for someone targeting healthspan extension. The honest research answer in 2026: signals are promising (cardiovascular event reduction in SELECT, cognitive-protection signals emerging) but not yet definitive for non-obese, non-diabetic populations. Off-label use in longevity practice has expanded but Phase III trials specifically powered for healthspan endpoints don't yet exist.

If you're in the metabolic-health-risk demographic (insulin resistance, elevated ApoB, central adiposity, family history of T2D or cardiovascular disease) — the cost-benefit math arguably favors initiation. If you're metabolically optimized already, the marginal benefit signal is much weaker.

For the underlying longevity context, see Function Health or Mito Health for comprehensive biomarker tracking — running labs first to identify whether GLP-1 therapy is even the right intervention for your physiology should be step one.

The bottom line

Read our full bmiMD spotlight for affiliate disclosure and pricing details. The brand's 60K+ active members and 4.9 star track record speak to operational quality. Whether GLP-1 therapy specifically is the right pick for your longevity stack is the question only you, your data, and your clinician can answer.

— Ryan, Founder